Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
In8Bio, Inc. (INAB) is a clinical-stage biopharmaceutical leader developing gamma-delta T cell immunotherapies for cancer treatment. This page provides investors and researchers with essential updates on clinical trials, regulatory developments, and strategic partnerships driving innovation in cellular therapies.
Access real-time announcements about the company's DeltEx platform advancements, chemotherapy-resistant cell therapies, and progress across solid tumor and hematologic malignancy programs. Our curated news collection includes earnings reports, trial data publications, and collaborative research milestones.
Key updates cover FDA designations, preclinical study results, and technology licensing agreements. All content is verified for accuracy and relevance to support informed decision-making in the oncology investment space.
Bookmark this page for streamlined access to In8Bio's latest scientific achievements and corporate developments. Check regularly for authoritative updates on one of biotech's most promising cancer immunotherapy innovators.
IN8bio presented details about its robust and reproducible gamma-delta T cell therapy manufacturing platform at ASGCT 2024. The data demonstrate significant advancements in the characterization of gamma-delta T cell-based therapies, showing increased potency, effector functions, and trafficking capabilities. The study evaluated T cell products from healthy donors and GBM patients, revealing consistent profiles and gene expression changes throughout the manufacturing process.
IN8bio, Inc. (Nasdaq: INAB) reported financial results for Q1 2024, highlighting progress in gamma-delta T cell programs. Key points include preclinical data on nsCAR platform targeting cancer cells, peer-reviewed publication on DeltEx Drug Resistant Immunotherapy for GBM, and dosing first patient in Phase 2 clinical trial. Financially, R&D expenses increased to $4.9 million, G&A expenses were $3.7 million, net loss was $8.6 million, and cash position stood at $13.0 million.
IN8bio, Inc. (Nasdaq: INAB) has dosed the first patient in a Phase 2 clinical trial of INB-400 for newly diagnosed glioblastoma multiforme (GBM). INB-400 is an autologous gamma-delta T cell therapy genetically engineered to survive chemotherapy and enhance cancer cell killing. The trial, expected to enroll up to 40 patients, aims to evaluate safety, tolerability, and overall survival rate at 12 months. INB-400 was granted Orphan Drug Designation in 2023 and is designed to work alongside standard-of-care treatments like temozolomide.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
